ViroGates A/S


ViroGates A/S

  • Price (DKK)56.60
  • Today's Change0.40 / 0.71%
  • Shares traded275.00
  • 1 Year change-65.06%
  • Beta0.8014
Data delayed at least 15 minutes, as of Feb 08 2023 11:21 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

ViroGates A/S is a Denmark-based medical technology company. Its develops a product line suPARnostic, which measures the amount of amount of soluble urokinase Plasminogen Activator Receptor protein (suPAR) in human blood. The plasma level of suPAR reflects immune activation and is increased in such infectious diseases as HIV-1-infection, malaria, tuberculosis, Streptococcus pneumonia bacteraemia, sepsis, pneumococcal pneumonia and bacterial and viral CNS infection. Also, high suPAR levels are associated with increased inflammation, disease progression and risk of mortality. Thus, measuring suPAR levels serves as a marker to determine chances for survival upon hospital admission, as well as for monitoring for prevention of disease progression and earlier intervention time point. suPARnostic has two versions: Quantitative Point of Care Quick Triage test, which serves for patient triage in acute care, and Quantitative ELISA Assay that aims at clinical routine use.

  • Revenue in DKK (TTM)10.48m
  • Net income in DKK-11.89m
  • Incorporated2000
  • Employees14.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
InDex Pharmaceuticals Holding AB0.00-43.86m160.81m7.00--0.628-----0.1312-0.13120.000.73250.00----0.00-15.20-55.64-15.71-63.58---11,950.82---110,729.40----0.0089---100.00---79.46------
Arctic Bioscience AS16.10m-24.41m166.38m----0.8076--10.33-1.50-1.500.986112.570.06910.62352.68---10.47---11.05--18.34---151.56--8.86-135.400.00--4.97---88.48------
Active Biotech AB publ0.00-37.62m167.58m11.00--12.96-----0.2525-0.25250.000.07440.00-------99.01-27.85-119.68-56.59-------472.29---76.420.2212---100.00---54.52------
NextCell Pharma AB4.19m-24.28m169.22m----2.42--40.42-1.08-1.080.18563.100.047525.742.66---27.56-37.04-29.10-39.18-54.71-125.45-579.98-700.5813.90--0.00--42.8660.97-40.71------
Magle Chemoswed Holding AB89.06m5.76m175.77m--30.531.8112.201.970.81230.812312.5613.710.54910.51994.87--3.55--4.67--90.10--6.47--0.7157--0.2523---7.16--130.57------
AlzeCure Pharma AB0.00-44.57m177.24m13.00--7.01-----1.54-1.540.000.62090.00----0.00-124.85---155.36--------------0.00-------8.99------
SoftOx Solutions AS4.53m-45.56m178.75m----6.31--39.42-6.55-6.550.6524.070.0992--1.31---99.67-44.89-144.08-54.35-----1,004.63-540.760.2779-130.300.2626---19.69139.15-74.85------
Kancera AB0.00-33.75m182.15m7.00--2.72-----0.7834-0.78340.001.280.00----0.00-42.84-68.54-47.22-86.44--92.88---5,941.59---99.010.00---100.00---12.80------
Hamlet Pharma AB0.00-11.29m183.54m4.00--11.33-----0.1569-0.15690.000.34390.00-------63.13-88.40-84.36-115.77-----------226.20---------122.71------
ViroGates A/S10.48m-11.89m188.30m14.00--10.53--17.98-3.63-3.633.165.340.48530.86687.85---55.08-46.55-62.05-52.0375.00-14.35-113.49-349.767.69-241.800.00--43.0015.745.73------
Moberg Pharma AB (publ)135.85k-10.83m192.28m----0.5324--1,415.44-0.2879-0.28790.00335.460.0004--0.0987---3.32---3.41--100.00---8,036.23-----241.380.0033--------------
SenzaGen AB19.90m-20.31m194.25m16.00--3.02--9.76-1.26-
Initiator Pharma A/S0.00-40.23m207.92m----5.63-----1.29-
Abliva AB51.85k-68.62m210.74m8.00--1.77--4,064.75-0.2269-0.22690.00020.17210.0005--0.00179,875.00-68.89-67.30-80.31-79.05-----132,358.20-76,095.50---35.460.00---30.0960.91-105.86---43.06--
Lifecare AS6.91m-12.01m214.01m----14.19--30.96-0.1652-0.16520.09590.19020.4309--2.26---74.86---93.53-------173.74------0.2527---70.34---508.85------
Lytix Biopharma AS947.51k-29.06m215.56m----1.89--227.50-1.12-1.120.03644.230.0072--0.2655---22.07---23.41-------3,066.50------0.00--466.67---14.16------
Data as of Feb 08 2023. Currency figures normalised to ViroGates A/S's reporting currency: Danish Krone DKK
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.